Polycystic ovary syndrome. Polycystic ovarian syndrome
Conditions
Interventions
Intervention 1: Intervention group: 25 grams of olive oil. Intervention 2: Intervention group: 25 grams of canola oil. Intervention 3: Control group: 25 grams of sunflower oil.
Sponsors
Esfahan University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
18 Years to 45 Years
Inclusion criteria
Inclusion criteria: The definitive diagnosis of PCOS based on diagnostic criteria (Rotterdam3) by the physician The absence of other endocrine disorders or the conditions that lead to some or most of the clinical manifestations and disorders associated with PCOS (such as congenital or non-classic adrenal hyperplasia, Cushing's syndrome, androgens secreting tumors, drugs induced hyperandrogenism, idiopathic hyperandrogenism, hirsutism Idiopathic, thyroid dysfunction, hyperprolactinemia, pregnancy, lactation and menopause) Non-use of any drug and / or surgical treatment for the clinical symptoms and disorders associated with PCOS other than OCP (such as spironolactone, finasteride, isotretinoin, letrozole, clomiphene, gonadotropins, metformin, cyproterone, rosiglitazone, pioglitazone, ovarian laparoscopic surgery, and Auxiliary reproductive technology) Absence of any severe or significant systemic disease requiring treatment such as any cancer; digestive, liver or endocrine disorders (such as celiac disease, Crohn's disease, ulcerative colitis), diabetes mellitus, hyperparathyroidism, hypercalcemia, or hyperphosphatemia); cardiovascular disorders (e.g. Uncontrolled hypertension or history of myocardial infarction); kidney disorders (such as renal failure, nephrotic syndrome); blood coagulation disorders (eg thalassemia, hemophilia); neurological disorders (such as epilepsy) or reproductive disorders associated with PCOS Ask a doctor or a patient Not taking any of these items: tobacco; alcohol; anti-estrogens (such as tamoxifen and raloxifene); oral or injectable corticosteroids (such as prednisone, prednisolone, dexamethasone, triamcinolone, hydrocortisone or betamethasone); lack of omega-3 supplementation Chains and long chains); effective drugs for insulin resistance such as metformin and sitagliptin Non-consumption of any canola and olive oil in the last 6 months as the main consumer oil Lack of any allergy, intolerance or harmful drug reaction to the supplementation of the studied oils Being in the age range of 18-45 years (people are not better off at the age of growth and menopause) Being in the BMI range above 25 and less than 40 Ability to understand the goals of the study and provide informed written consent The desire to participate in the study Weight constant over the past 6 months (self report) Lack of Pregnancy and Breastfeeding
Exclusion criteria
Exclusion criteria: The onset of a dose or any change in dosage in the above drugs or the change in the type or dose of OCP consumed during the study period Getting pregnant during the study period Incidence of severe side effects or signs of poisoning with supplements used during the study period Failure to adhere to the study protocol The acceptance of less than 80% of the intervention (consumption of less than 80% of the total intervention oil that should be consumed during the 10-week intervention period will be considered as a low admission)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Lipid profile. Timepoint: At the beginning of the study, 5 weeks after the intervention and the end of the study. Method of measurement: Spectrophotometric method.;Anthropometric Indicators. Timepoint: At the beginning of the study, 5 weeks after the intervention and the end of the study. Method of measurement: Measurements with biometric impedance analysis (BIA) and meters.;Fatty liver grade. Timepoint: At the beginning of the study, 5 weeks after the intervention and the end of the study. Method of measurement: sonography.;Mood disorder score. Timepoint: At the beginning of the study, 5 weeks after the intervention and the end of the study. Method of measurement: DASS-21 questionnaire.;Inflammatory Indicators. Timepoint: At the beginning of the study, 5 weeks after the intervention and the end of the study. Method of measurement: ELISA. | — |
Secondary
| Measure | Time frame |
|---|---|
| Clinical signs including hirsutism and the interval between menstruation. Timepoint: At the beginning of the study, 5 weeks after the intervention and the end of the study. Method of measurement: MFGS questionnaire And the question of the patient.;Blood pressure. Timepoint: At the beginning of the study, 5 weeks after the intervention and the end of the study. Method of measurement: Mercury barometric. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMaryam Yahay
Esfahan University of Medical Sciences
Outcome results
None listed